SD Biosensor Inc (137310) - Net Assets
Based on the latest financial reports, SD Biosensor Inc (137310) has net assets worth ₩2.41 Trillion KRW (≈ $1.63 Billion USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩2.90 Trillion ≈ $1.97 Billion USD) and total liabilities (₩495.94 Billion ≈ $336.09 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 137310 strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩2.41 Trillion |
| % of Total Assets | 82.91% |
| Annual Growth Rate | 60.25% |
| 5-Year Change | 6.06% |
| 10-Year Change | N/A |
| Growth Volatility | 167.71 |
SD Biosensor Inc - Net Assets Trend (2019–2025)
This chart illustrates how SD Biosensor Inc's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see 137310 market cap.
Annual Net Assets for SD Biosensor Inc (2019–2025)
The table below shows the annual net assets of SD Biosensor Inc from 2019 to 2025. Also explore 137310 net assets growth trend to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | ₩2.34 Trillion ≈ $1.58 Billion |
-20.31% |
| 2024-12-31 | ₩2.93 Trillion ≈ $1.99 Billion |
+3.56% |
| 2023-12-31 | ₩2.83 Trillion ≈ $1.92 Billion |
-3.91% |
| 2022-12-31 | ₩2.95 Trillion ≈ $2.00 Billion |
+33.74% |
| 2021-12-31 | ₩2.20 Trillion ≈ $1.49 Billion |
+190.86% |
| 2020-12-31 | ₩757.55 Billion ≈ $513.38 Million |
+449.29% |
| 2019-12-31 | ₩137.91 Billion ≈ $93.46 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to SD Biosensor Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 14917.3% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩1.42 Trillion | 60.99% |
| Other Components | ₩908.75 Billion | 39.01% |
| Total Equity | ₩2.33 Trillion | 100.00% |
SD Biosensor Inc Competitors by Market Cap
The table below lists competitors of SD Biosensor Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Deluxe Family Co Ltd
SHG:600503
|
$499.41 Million |
|
Shanghai Shine-Link Intl
SHG:603648
|
$499.57 Million |
|
Dutch Lady Milk Industries Bhd
KLSE:3026
|
$499.72 Million |
|
Nagarro SE
XETRA:NA9
|
$499.88 Million |
|
Xiamen Comfort Science&Technology Group Co Ltd
SHE:002614
|
$499.26 Million |
|
Gruvaktiebolaget Viscaria
ST:VISC
|
$499.15 Million |
|
Nueva Expresión Textil S.A.
MC:NXT
|
$499.14 Million |
|
Bradespar S.A
SA:BRAP3
|
$499.01 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in SD Biosensor Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,923,334,168,420 to 2,329,681,445,810, a change of -593,652,722,610 (-20.3%).
- Net loss of 512,106,082,390 reduced equity.
- Dividend payments of 24,183,414,160 reduced retained earnings.
- Share repurchases of 11,574,629,460 reduced equity.
- New share issuances of 164,820,170 increased equity.
- Other factors decreased equity by 45,953,416,770.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-512.11 Billion | -21.98% |
| Dividends Paid | ₩24.18 Billion | -1.04% |
| Share Repurchases | ₩11.57 Billion | -0.5% |
| Share Issuances | ₩164.82 Million | +0.01% |
| Other Changes | ₩-45.95 Billion | -1.97% |
| Total Change | ₩- | -20.31% |
Book Value vs Market Value Analysis
This analysis compares SD Biosensor Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.32x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 4.31x to 0.32x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | ₩1429.57 | ₩6160.00 | x |
| 2020-12-31 | ₩8015.86 | ₩6160.00 | x |
| 2021-12-31 | ₩21316.76 | ₩6160.00 | x |
| 2022-12-31 | ₩28794.15 | ₩6160.00 | x |
| 2023-12-31 | ₩23079.02 | ₩6160.00 | x |
| 2024-12-31 | ₩23893.70 | ₩6160.00 | x |
| 2025-12-31 | ₩19475.81 | ₩6160.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently SD Biosensor Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -21.98%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -72.07%
- • Asset Turnover: 0.22x
- • Equity Multiplier: 1.39x
- Recent ROE (-21.98%) is below the historical average (17.47%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 2.36% | 4.32% | 0.43x | 1.27x | ₩-10.19 Billion |
| 2020 | 82.30% | 36.51% | 1.15x | 1.95x | ₩540.83 Billion |
| 2021 | 48.61% | 36.34% | 0.97x | 1.37x | ₩845.72 Billion |
| 2022 | 30.95% | 31.08% | 0.90x | 1.11x | ₩616.93 Billion |
| 2023 | -16.56% | -71.33% | 0.17x | 1.34x | ₩-750.08 Billion |
| 2024 | -3.37% | -14.17% | 0.18x | 1.33x | ₩-390.74 Billion |
| 2025 | -21.98% | -72.07% | 0.22x | 1.39x | ₩-745.07 Billion |
Industry Comparison
This section compares SD Biosensor Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $96,296,054,843
- Average return on equity (ROE) among peers: -3.91%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| SD Biosensor Inc (137310) | ₩2.41 Trillion | 2.36% | 0.21x | $499.36 Million |
| Shinhung (004080) | $84.68 Billion | 1.36% | 0.55x | $88.95 Million |
| HansBiomed Corporation (042520) | $67.12 Billion | -10.76% | 0.81x | $163.88 Million |
| JVM Co. Ltd (054950) | $123.61 Billion | 4.69% | 0.46x | $180.70 Million |
| U&I Corporation (056090) | $27.09 Billion | -45.35% | 1.38x | $83.27 Million |
| Huvitz Co. Ltd (065510) | $110.57 Billion | 9.02% | 0.82x | $48.95 Million |
| Vieworks Co. Ltd (100120) | $161.42 Billion | 15.00% | 0.12x | $153.21 Million |
| Corentec Co Ltd (104540) | $20.12 Billion | 2.40% | 0.93x | $34.70 Million |
| Hironic Co. Ltd (149980) | $42.80 Billion | 1.68% | 0.04x | $49.23 Million |
| Humasis Co. Ltd (205470) | $229.26 Billion | -13.28% | 0.45x | $225.45 Million |
About SD Biosensor Inc
SD Biosensor, Inc., together with its subsidiaries, operates as an in-vitro diagnostic company in South Korea, India, Asia, Europe, the Americas, and Africa. The company offers STANDARD Q, which provides rapid diagnostic products; STANDARD F, a fluorescence immunodiagnostic system for various qualitative and quantitative diagnosis items; STANDARD E, an enzyme immunoassay diagnosis for large-volum… Read more